Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 9
Submit an article Journal homepage
107
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia

Jill FulcherDivision of Hematology, Department of Medicine, University of Ottawa and Ottawa Health Research Institute, Ottawa, Canada; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-0369-5034
ORCID Icon,
Eugene LeungDivision of Nuclear Medicine, Department of Medicine, University of Ottawa and Ottawa Health Research Institute, Ottawa, Canada
,
Grace ChristouDivision of Hematology, Department of Medicine, University of Ottawa and Ottawa Health Research Institute, Ottawa, Canada;
,
Christopher BredesonDivision of Hematology, Department of Medicine, University of Ottawa and Ottawa Health Research Institute, Ottawa, Canada;
&
Mitchell SabloffDivision of Hematology, Department of Medicine, University of Ottawa and Ottawa Health Research Institute, Ottawa, Canada; ORCID Iconhttp://orcid.org/0000-0002-0122-6138
ORCID Icon
Pages 2271-2273 | Received 03 Jan 2020, Accepted 19 Apr 2020, Published online: 19 May 2020

References

  • Bassan R, Bruggemann M, Radcliffe h-S, et al. A systematic review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019;104(10):2028–2039.
  • Dhakal P, Kaur J, Gundabolu K, et al. Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents? Leuk Lymphoma. 2020;61(1):7–17.
  • Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017;92(9):858–865.
  • Demosthenous C, Lalayanni C, Iskas M, et al. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Curr Probl Cancer. 2019;43(3):222–227.
  • Gaudichon J, Jakobczyk H, Debaize L, et al. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues. Blood Rev. 2019;36:40–56.
  • Weng J, Lai P, Qin L, et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J Hematol Oncol. 2018;11(1):25.
  • Li S, Zhang J, Wang M, et al. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. Br J Haematol. 2018;181(3):360–371.
  • Bertamini L, Nanni J, Marconi G, et al. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. BMC Cancer. 2018;18(1):1117.
  • Da Silva WF, Marquez GL, Salim RC, et al. Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicin. Hematol, Transfus Cell Ther. 2019;41(4):356–359.
  • Marks DI, Moorman AV, Chilton L, et al. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica. 2013;98(6):945–952.
  • Wolfl M, Rasche M, Eyrich M, et al. Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL. Blood Adv. 2018;2(12):1382–1385.
  • Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474–2487.
  • Marks DI, DeAngelo DJ, Stelljes M, et al. Poster session presented at: the 45th Annual Meeting of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2019;54:144–619.
  • Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271–1280.
  • Mohty M, Malard F, Abecasis M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group [published online ahead of print, 2019 Oct 1]. Bone Marrow Transplant. 2020;55(3):485–495.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.